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1. Introduction 
Lower extremity peripheral arterial disease (PAD) is a disorder characterized by 
atherosclerotic narrowing or occlusion of the lower limb arteries. In addition to its 
association with impaired mobility and functional status, PAD is a marker of systemic 
atherosclerosis and is associated with a high incidence of cardiovascular events such as 
stroke, myocardial infarction (MI) and vascular death.  
2. Epidemiology 
Eight to 12 million people in United States have PAD (Allison et al. 2007). Only ~10% of 
patients with PAD have classic intermittent claudication (IC), ~50% have atypical leg 
symptoms and ~40% are asymptomatic (Hiatt 2001). Its prevalence significantly increases 
with age; 12 – 20% of those above the age of 65 years suffer from PAD (Ostchega al. 2007). 
The prevalence of PAD is similar in men and women; however men are more likely to have 
symptomatic disease (Ness et al. 2000; Aronow et al. 2002; Selvin and Erlinger 2004; 
Ostchega et al. 2007).  
PAD is a polyvascular disease. Sixty to 90% of patients with PAD also have significant 
coronary artery disease (CAD) and up to 25% have significant carotid artery stenosis 
(Hertzer et al. 1984; Klop et al. 1991; Valentine et al. 1994; Cheng et al. 1999; McFalls et al. 
2004; Steg et al. 2007). In a study at the Cleveland Clinic, all patients undergoing vascular 
surgery between 1978 and 1981 had coronary angiogram. Only 10% of those patients had 
normal coronaries and 28% had severe 3 vessel coronary artery disease requiring surgical or 
catheter based intervention (Hertzer et al. 1984). Patients with PAD have a 3-fold greater 10-
year risk (RR, 3.1; 95% CI, 1.9–4.9) of all-cause death and a 6-fold greater risk (RR, 6.6; 95% 
CI, 2.9–14.9) of cardiovascular (CV)-related death compared to patients without PAD 
(Criqui et al. 1992). In the REACH registry, by one year , 21% of patients with PAD had 
developed MI, stroke, cardiovascular death or hospitalization compared with 15% of 
patients with CAD (Steg et al. 2007).  
3. Risk factors for PAD 
Risk factors for PAD are similar to those for atherosclerotic disease in other vascular beds 
with some variation in their individual attributable risks.  
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3.1 Cigarette smoking 
A strong predictor of prevalent PAD and its progression; it also predicts bypass graft and 
endovascular intervention failure. (Sapoval et al. 1996; Hirsch et al. 2001; Willigendael et al. 
2005; Aboyans et al. 2006). Smoking increases the risk of lower extremity peripheral arterial 
disease by 2- to 6-fold and the risk of intermittent claudication by 3- to 10-fold (Kannel and 
McGee 1985; Smith et al. 1990; Bowlin et al. 1994; Meijer et al. 1998). 80% of patients with 
PAD have a smoking history (Smith et al. 1990; Meijer et al. 1998). Interestingly, cigarette 
smoking is a stronger risk factor for PAD than for CAD with smoker’s having a 2 to 3 times 
greater likelihood of developing PAD than CAD (Hirsch et al. 2001). It is also an 
independent predictor of the risk for unplanned urgent revascularization of the lower 
extremities following initial successful treatment (Shamma et al. 2003). With an increasing 
number of pack years, there is an increase in severity of disease, increased risk of 
amputation, peripheral graft occlusion and overall mortality.  
3.2 Diabetes Mellitus (DM) 
The risk of prevalent PAD doubles in the setting of impaired glucose tolerance (Beckman et 
al. 2002) and increases by 2 to 4 fold in patients with overt diabetes mellitus. PAD presents 
at an earlier age in diabetics; the prevalence of PAD is ~ 20% in diabetic patients older than 
40 years and increases to ~30% among those older than 50 years (Hirsch et al. 2001; 2003). 
Diabetics tend to have more severe degrees of stenosis and a higher preponderance toward 
calcification as compared to non-diabetic patients with PAD (Jude et al. 2001). PAD is more 
likely to remain asymptomatic in diabetics until very advanced. Finally, poor glvcemic 
control is associated with more rapid PAD progression, increased risk of amputation and 
mortality (Jude et al. 2001; Beckman et al. 2002).  
3.3 Hypertension and dyslipidemia 
Although the attributable risk for these factors is less than for DM or smoking, their 
adverse impact is clear from multiple studies. Uncontrolled higher blood pressures are 
associated with increased severity of PAD (Ness et al. 2000; Hirsch et al. 2001; Selvin and 
Erlinger 2004; Ostchega et al. 2007). Elevated total and LDL cholesterol, low HDL 
cholesterol and hypertriglyceridemia are associated with prevalent PAD (Kannel and 
Shurtleff 1973; Fowkes et al. 1992; Hiatt et al. 1995; Murabito et al. 2002). The risk of 
developing PAD increases by 5 – 10% with each 10 mg/dl increase in total cholesterol 
(Ingolfsson et al. 1994; Murabito et al. 1997).  
3.4 Renal insufficiency 
Patients with chronic kidney disease (creatinine clearance <60 ml/min) and end stage renal 
disease have a higher prevalence of IC and low ankle-brachial index (ABI) as compared to 
patients with normal renal function (O'Hare et al. 2004). They also have a higher prevalence 
of critical limb ischemia and increased incidence of peri and post operative mortality related 
to lower extremity revascularization procedures (O'Hare et al. 2003). Potential mechanisms 
include altered calcium-phosphorus, homocysteine, and lipoprotein (a) metabolism and 
altered inflammatory and coagulation pathways. 
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3.5 Inflammation 
A number of inflammatory markers are associated with prevalent PAD and outcomes 
among those with PAD. In a meta-analysis, the odds ratio for PAD in patients with 
increased homocysteine was 6.8 (Boushey et al. 1995). 30-40% of PAD patients have elevated 
homocysteine levels as compared with 3-5% of the general population (Hajjar 1993). 
Elevated C – reactive protein and D-dimer are associated with increased cardiovascular 
mortality in PAD patients (Vidula et al. 2008).  
3.6 Age 
The Prevalence of PAD increases with age. In the NHANES study, the prevalence of PAD 
increased significantly with each decade since beyond 40 years (Selvin and Erlinger 2004) 
(Table 1). In a German epidemiologic study, 21% of the patients above the age of 65 years 
had symptomatic or asymptomatic PAD yet again demonstrating increased incidence of 
PAD with age (Diehm et al. 2009).  
 
Table 1. In the NHANES study, prevalence of PAD increased significantly with age. 
3.7 Race/ethnicity 
The prevalence of PAD varies by ethnicity and race. Non-hispanic blacks have the highest 
prevalence, followed by Mexican Americans and non-Hispanic whites, with 19.5%, 15.6% 
and 11.7% above the age of 60 years having PAD, respectively (Ostchega et al. 2007). It is 
believed that these relationships are mediated by a genetic predisposition in part secondary 
to variations in atherogenic and prothrombotic factors (Folsom et al. 1992; Conlan et al. 1993; 
Gerhard et al. 1999). 
4. Clinical presentation 
PAD can present in the following forms (Hirsch et al. 2006):  
4.1 Intermittent claudication: Exertional symptoms such as muscle pain, cramping, 
discomfort or fatigue in the legs which resolves with rest of 10 minutes or less. However, 
these 'classic' symptoms are seen in only 10 % of patients with PAD.  
4.2 “Atypical” leg pain: Exertional leg symptoms which may not always resolve with rest or 
are not consistently reproducible.  
4.3 Asymptomatic: 40 % of patients with PAD have no leg symptoms but most will have 
some other form of functional limitations.  
4.4 Acute limb ischemia: A potentially limb threatening syndrome, classically manifest by one 
of more of the following five “P’s” – pain, pulselessness, paralysis, paresthesias and pallor.  
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4.5 Chronic limb ischemia (also known as 'critical limb ischemia [CLI]): Accounts for 1-2% of 
all patients with PAD. It presents as rest pain, non-healing ulcers and/or gangrene.  
The severity of symptoms usually correlates with degree of stenosis, adequacy of collateral 
circulation and level of exertion. Location of the discomfort may shed light on the location of 
stenosis (Table 2).  
 
Table 2. Level of disease and associated symptoms  
5. Natural history of PAD 
Over a 5-year period, only 1-2% of claudicants and asymptomatic patients develop CLI. 
Nevertheless, the overall mortality rate is 15 – 30% (75% of which is cardiovascular) and risk 
of non-fatal MI or stroke 20% at 5 years. Patients with CLI have much worse outcomes with 
an annual CV mortality of 25% and annual amputation rate of 25%.  
It is noteworthy that the burden of PAD may not correlate with the presence or absence of 
claudication. Patients who are more physically active are more likely to present with 
claudication than those who lead a sedentary lifestyle. Patients who are too sedentary to 
claudicate may present with CLI as their first manifestation of disease.  
6. Classification of PAD 
The Rutherford and Fontaine classifications (Table 3) are frequently utilized to classify PAD 
symptom severity.  
 
Table 3. Rutherford and Fontaine classification for PAD. 
7. Physical exam 
A comprehensive vascular history and physical exam is vital in the evaluation and 
appropriate treatment of patient with PAD or suspected PAD. Current ACC / AHA 
guidelines recommend a complete vascular exam (class I B) for patients with intermittent 
claudication (Hirsch et al. 2006). 
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The key components of physical exam are:  
 Bilateral arm blood pressure (to screen for subclavian stenosis/upper extremity PAD) 
 Cardiac examination 
 Assessment of the abdomen for aortic aneurysmal and stenotic disease 
 Thorough Examination of legs and feet 
 Pulse  
 Carotid  
 Radial/ulnar 
 Femoral 
 Popliteal 
 Dorsalis pedis (DP) 
 Posterior tibial (PT) 
Pulse should be graded on a scale of 0-3. 0=absent, 1=dampened, 2=normal or 3=bounding. 
If no pulse is palpable on exam, a Doppler exam using a hand-held continuous wave device 
should be performed. An absent or abnormal PT pulse has a very high specificity for 
diagnosis of PAD. An absent or abnormal DP is non-specific due to a high prevalence of 
absent or anomalous DP in the general population.  
 It is also vital to asses for vascular bruits (carotid, abdominal, femoral, and popliteal) 
 Other characteristics that may be seen in lower extremity PAD:  
 Hair loss 
 Nail hypertrophy 
 Rapid elevation pallor or dependent rubor.  
 Foot examinations should be performed at each visit for patients with PAD to 
assess for tissue loss (i.e., ulcers or gangrene) as well as for signs of other foot 
pathology such as callous formation or neuropathy.  
8. Screening for asymptomatic patients 
In the PAD Awareness, Risk and Treatment: New Resources for Survival (PARTNERS) 
study, 6979 patients aged ≥ 70 years or aged 50-69 years with a history of cigarette smoking 
or diabetes were screened with ABI’s  (Hirsch et al. 2001). PAD (defined as an ABI of ≤ 0.90) 
was diagnosed in 29% of this cohort. This diagnosis would have been missed in 85% to 90% 
had physicians relied solely on patients presenting with intermittent claudication (Hirsch et 
al. 2001). Even patients with IC infrequently report this symptom as they attribute it to the 
normal aging process (Dormandy and Rutherford 2000). A German epidemiologic study 
which included 6880 patients > 65 years of age reported that 21% of these patients had 
asymptomatic or symptomatic PAD (Diehm et al. 2009). Given that up to 50% of patients 
with PAD may be asymptomatic, it is critical that these high risk patients are identified so 
that appropriate interventions may be initiated to prevent the associated morbidity and 
mortality. ACC /AHA guidelines recommend screening ABI’s among high risk patients 
(class IC) defined as individuals with 1 or more of the following: exertional leg symptoms, 
non-healing wounds, age 65 years and older, or 50 years and older with a history of 
smoking or diabetes (Rooke et al. 2011).  
The ADA also recommends that any diabetic patient above the age of 50 years who has a 
normal ABI should have ABI’s repeated every 5 years (American Diabetic Association 2003).  
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9. Diagnostic evaluation 
It is necessary to differentiate claudication from other conditions causing leg pain when 
evaluating patients with PAD. Patients may have an abnormal ABI and present with leg 
pain unrelated to PAD. Claudication may be confused with pseudoclaudication resulting 
from spinal stenosis, nerve compression syndromes, arthritic pain or venous claudication. 
Certain clinical features help differentiate these conditions Questionnaires have also been 
frequently used for identifying, monitoring, assessing severity of PAD and treatment 
success. The Rose claudication questionnaire is a simple screening tool for claudication 
which can be administered by asking 2 simple questions; “Do you get pain in either leg 
when you walk?” and “Does the pain go away when you stop walking?” If the answer to 
both the question is yes then the like hood for PAD is 95% (Rose 1962). There is an updated 
version of the World Health Organization Rose Questionnaire and also the Edinburgh 
Claudication Questionnaire which are used to diagnose PAD and the Walking Impairment 
Questionnaire, the Peripheral Artery Questionnaire and the Medical Outcomes Study 36-
Item Short Form Health Survey are used to assess severity of PAD and assess response to 
therapy (Criqui al. 1985; Leng and Fowkes 1992; Criqui et al. 1996; Spertus et al. 2004). 
10. Diagnostic tests 
Physiological studies such as the ABI, segmental limb pressures, or pulse-volume waveform 
analysis can help identify functional limb perfusion abnormalities. Imaging methods, such 
as duplex ultrasonography, CT angiography (CTA) and magnetic resonance angiography 
(MRA) provide detailed anatomical, but less frequently functional information on limb 
perfusion. Diagnostic modalities and respective clinical indications appear in Table 4. 
10.1 Ankle-Brachial Index 
ABI measurement is the universally accepted standard for the initial diagnostic evaluation of 
patients with suspected PAD and for high risk asymptomatic patients (Hirsch, Haskal et al. 
2006; Mohler and Giri 2008; Rooke et al. 2011). It is simple, reliable, extremely sensitive (79 - 
95%) and specific (96-100%) and can be performed in a primary care office in < 15 minutes 
(Fowkes 1988; Lijmer et al. 1996). The ABI is calculated by measuring the systolic blood 
pressure in each arm (brachial artery) and ankle (dorsalis pedis and posterior tibial arteries) 
using a hand held Doppler device in a patient who has been resting in the supine position for 
10 minutes. The right ABI = higher right ankle pressure/higher pressure in either arm; the left 
ABI = higher left ankle pressure/higher pressure in either arm. An ABI ≤ 0.90 suggests PAD 
with ≥ 50% stenosis in at least one artery. (Fowkes 1988; Lijmer, Hunink et al. 1996).  
Based on publication of the results of the Ankle Brachial Index Collaboration, a normal ABI 
range is defined as between 1.00 to 1.40, and abnormal values continue to be defined as 
those ≤0.90. ABI values of 0.91 to 0.99 are considered "borderline" and values ≥1.40 indicates 
noncompressible arteries (Fowkes, Murray et al. 2008; Rooke, Hirsch et al. 2011). 
In addition to its diagnostic utility, the ABI also provides important prognostic and 
functional information. The relative risk of mortality increases by 3.1% with a decrease of 
0.50 in ABI. Sikkink et al followed 150 patients who were  >40 years of age and had ABI< 
0.90 and found that the cumulative survival at 5 years was 63% for patients with an ABI of < 
0.50, 71% for patients with an ABI of 0.50 to 0.69, and 91% for those with an ABI of ≥ 0.70 
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(Sikkink et al. 1997). McDermott and colleagues found that poor functional outcomes were 
associated with lower ABI’s (McDermott et al. 2002). Interestingly, functional outcomes did 
not correlate with leg symptoms, again confirming that leg symptoms are a poor marker for 
identifying PAD severity.  
Resting ABI may be insensitive for detecting aorto-iliac occlusive disease. ABI after exercise 
should be performed in these patients if PAD is suspected. If resting values in patients with 
intermittent claudication are normal, then ABI should be repeated after exercise. 
Incompressible arteries (e.g., elderly, diabetes, renal failure) may yield falsely normal or 
elevated ABI measurements. Toe- brachial index (TBI) measurement or pulse volume 
recording measurements should be performed in these patients as they are more accurate in 
this setting(Rooke et al. 2011). 
10.2 Segmental Pressure Examination (SPE) and Pulse Volume Recordings (PVR) 
SPE is a physiological test helpful in identifying location of individual arterial stenoses. It is 
performed by placing blood pressure cuffs at the upper thigh, the lower thigh, the upper 
calf and the lower calf above the ankle. Systolic blood pressure measurements are obtained 
at all these sites and both brachial arteries. A difference of ≥ 20 mm Hg between two 
adjacent segments is considered physiologically significant. For example, a significant 
pressure gradient between left upper thigh cuff and left lower thigh cuff would indicate a 
physiologically significant stenosis in the left superficial femoral artery. As with the ABI, 
pressures may be elevated or uninterpretable in patients with non-compressible vessels. 
Pulse volume recordings are performed by measuring volume changes in the limb along 
with segmental pressure recordings (Darling et al. 1972). Segmental pressure examination 
when performed with pulse volume recordings has an overall accuracy of 90 – 95%  in 
assessing the location and severity of arterial stenosis (Symes et al. 1984).  
10.3 Duplex ultrasound 
It is recommended by ACC / AHA guidelines (Class I) for routine surveillance after 
femoral-popliteal or femoral-tibial pedal bypass with a venous conduit (Hirsch et al. 2006).  
The 2011 ACC/AHA guidelines recommend that segmental pressures, Doppler waveform 
analysis, pulse volume recordings, or ABI with duplex ultrasonography (or some 
combination of these methods) to document the presence and location of PAD in the lower 
extremity can be used (Rooke et al. 2011). In general, imaging studies are reserved for 
patients with PAD in whom revascularization is planned, for bypass graft or percutaneous 
vascular intervention surveillance or for cases in which the diagnosis of PAD or etiology of 
PAD is unclear such as arterial aneurysm, fibromuscular dysplasia, entrapment syndrome 
or vasculitis. Imaging studies are also used to diagnose PAD in patients with non-
compressible vessels such as those with ABI > 1.3.  
Physiological testing such as ABI and PVR are adequate for asymptomatic patients. For 
symptomatics (claudication or pseudoclaudication) ABI and PVR with or without exercise, 
duplex or dopler ultrasound are utilised. CTA, MRA or duplex / doppler ultrasound are 
usually used for patients considered for revascularization as well as for post endovascular 
interventions and follow ups as well as for post vein graft follow ups.  
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11. Management of Peripheral Arterial Disease 
Guidelines for the management of PAD have been published by 
a. American college of  Cardiology / American Heart Association which was a 
Collaborative Report from the American Association for Vascular Surgery/ Society for 
Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society 
for Vascular Medicine and Biology, Society of Interventional Radiology, and the 
ACC/AHA Task Force on Practice Guidelines  
b.  Scottish Intercollegiate Guidelines Network (SIGN), and  
c. Trans-Atlantic Inter-Society Consensus (TASC) II (Dormandy and Rutherford 2000; 
Hirsch et al. 2006; Network 2006; Norgren et al. 2007).  
Each of these guidelines focuses on management of PAD as a two-tiered process. First and 
foremost, they recommend cardiovascular risk reduction through vascular risk factor 
modification and antiplatelet therapy and second, symptom-guided therapy including 
supervised exercise, pharmacological interventions and revascularization procedures, when 
needed.  
11.1 Cardiovascular risk factor modification 
11.1.1 Smoking cessation 
Patients with PAD should be referred to a formal smoking cessation program including 
pharmacotherapy when appropriate. A Cochrane review of 20 prospective cohort studies 
showed that smoking cessation is associated with a 36% risk reduction in cardiovascular 
events in patients with known atherosclerotic disease (Critchley and Capewell 2004) and is 
recommended by all three guidelines(Dormandy and Rutherford 2000; Hirsch et al. 2006; 
Network 2006; Norgren et al. 2007; Rooke et al. 2011); Smoking cessation is achieved in 
approximately 5% of patients with physician encouragement and advice along with regular 
follow-ups and as compared to 0.1% without physician intervention at 1 year (Law and 
Tang 1995). Success rates are higher with interventions such as nicotine replacement, 
bupropion or varenicline. When compared with usual care,  formal smoking cessation 
program which consisted of a strong physician message and 12 two-hour group sessions, 
using behavior modification and nicotine gum had a higher success rate at 5 years (22% vs. 
5%) (Anthonisen et al. 2005). Abstinence rates with bupropion at 3-, 6- and 12- month follow 
up are 34%, 27% and 22% respectively, compared with 15%, 11% and 9%, for 
placebo(Tonstad et al. 2003). A combination of bupropion and nicotine replacement is 
superior to nicotine replacement alone, however but has similar in efficacy to only 
monotherapy with bupropion (Jorenby et al. 1999). Varenicline has been proven effective in 
smokers with cardiovascular disease including those with PAD. Rigotti et al conducted a 
multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and 
safety of varenicline (12 weeks treatment) with placebo  showed a continuous abstinence 
rate was higher for varenicline than placebo during weeks 9 through 12 (47.0% versus 
13.9%;) and weeks 9 through 52 (19.2% versus 7.2%). The varenicline and placebo groups 
did not differ significantly in cardiovascular mortality, all-cause mortality, cardiovascular 
events, or serious adverse events. (Rigotti et al. 2010). Another RCT compared varenicline 
vs. bupropion vs placebo showed varenicline was more efficacious than bupropion or  
placebo in short term (9-12 weeks) (43.9% vs. 29.8%  vs. 17.6)% as well as long term period 9 
– 52 weeks) (23% vs. 14.6% vs. 10.3%) (Jorenby et al. 2006).  
www.intechopen.com
 
Lower Extremity Peripheral Arterial Disease 
 
127 
11.1.2 Diabetes Mellitus 
Approximately 20-30% in patients with DM have PAD (Marso and Hiatt 2006). The severity 
of PAD in this cohort correlates with the duration and severity of DM (Selvin et al. 2004; 
Wattanakit et al. 2005). With every 1% increase in glycosylated hemoglobin levels, the risk of 
PAD increases by 28% (Selvin et al. 2004)and risk of intermittent claudication by 3.5- and 
8.6-fold in men and women, respectively (Kannel and McGee 1985). DM may also lead to 
peripheral neuropathy and decreased resistance to infection, which increases the risk of 
infected foot ulcers. Patients with DM are at a higher risk of amputation and have reduced 
primary patency after revascularization as compared to non-diabetics (Bild et al. 1989; 
DeRubertis et al. 2008). The UKPDS study showed that the overall microvascular 
complication rate decreased by 25% by lowering blood glucose levels in type 2 diabetes with 
intensive therapy, which achieved a median HbA1c of 7.0% compared with conventional 
therapy with a median HbA1c of 7.9%. No significant effect on cardiovascular complications 
was observed. A non-significant (p = 0.052) 16% reduction in the risk of combined fatal or 
nonfatal myocardial infarction and sudden death was observed (UKPDS 1998). 
The American Diabetic Association recommends maintaining hemoglobin A1c below 7% to 
reduce microvascular events (ADA 2010). This recommendation is endorsed by all three 
PAD guidelines. The ADA also recommends comprehensive foot care including proper 
footwear, regular podiatric foot and nail care, daily foot inspection, skin cleansing, and use 
of topical moisturizing creams (ADA 2010).  
11.1.3 Dyslipidemia 
The Heart Protection Study (HPS) randomized 20,536 high-risk patients to 40 mg/d of 
simvastatin or placebo, including 6,748 patients with PAD. PAD patients taking statins had 
a 25% cardiovascular risk reduction at 5 years independent of baseline LDL level (HPS 
2002). Statin use is also associated with reduction in the risk of new or worsening 
claudication (Pedersen, Kjekshus et al. 1998). A RCT comparing high dose atorvastatin (80 
mg) vs. placebo irrespective of baseline LDL cholesterol showed that high dose atorvastatin 
improves pain-free walking distance and community-based physical activity in patients 
with intermittent claudication, however there was no change noted in the maximal walking 
time. This beneficial effect was noted over statins cardiovascular risk reduction benefits. 
(Mohler, Hiatt et al. 2003).  
The AHA / ACC and TASC 2 guidelines recommend the following for dyslipidemia 
management in patients with PAD (Dormandy and Rutherford 2000; Smith et al. 2001; 
Hirsch et al. 2006; Norgren, Hiatt et al. 2007).  
 All patients should have low-density lipoprotein (LDL)- cholesterol <2.59 mmol/L 
(<100 mg/dL). 
 In patients with PAD and a history of vascular disease in other beds (e.g. coronary artery 
disease) it is reasonable to lower LDL cholesterol levels to <1.81 mmol/L (<70 mg/dL). 
 In patients with elevated triglyceride levels where the LDL cannot be accurately 
calculated, the LDL level should be directly measured and treated to the above targets. 
Alternatively, the non-HDL (high-density lipoprotein) cholesterol level can be 
calculated with a goal of <3.36 mmol/L (<130 mg/dL), and in high risk patients <2.59 
mmol/L (<100 mg/Dl). 
 Dietary modification should be the initial intervention to control abnormal lipid levels [B]. 
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 In symptomatic PAD patients, statins should be the primary agents to lower LDL 
cholesterol levels to reduce the risk of cardiovascular events [A]. 
The SIGN guidelines recommend statins for patients with PAD and total cholesterol level > 
3.5 mmol/l  (63 mg/dl) (Network 2006). 
The ACC/AHA  and TASC II guidelines also recommended considering niacin / fibrates for 
raising HDL cholesterol and lowering triglycerides in patients with PAD who have 
abnormalities in these lipid fractions. Recently, the randomized trial, AIM – HIGH, failed to 
reduce the incidence of cardiovascular events among patients with CAD at 3 years and was 
terminated prematurely, raising questions about the benefit of niacin in patients with 
atherosclerotic vascular disease (http://www.aimhigh-heart.com/ 2011).  
11.1.4 Management of hypertension 
Blood pressure lowering by any pharmacological means reduces cardiovascular risk 
(Chobanian et al. 2003); however angiotensin converting enzyme inhibitors (ACEI) have 
benefit in patients with PAD beyond their effect on lowering blood pressure. The Heart 
Outcomes Prevention Evaluation (HOPE) study showed a 22% reduction in risk of MI, stroke, 
or vascular death in patients randomized to ramipril compared to placebo, independent of the 
blood pressure–lowering effect (Yusuf et al. 2000). Although once thought to worsen 
claudication, the safety of beta blockers, has been demonstrated in a meta-analysis of 11 trials 
of patients with PAD (Radack and Deck 1991); these agents are of benefit of patients with 
CAD, particularly among those with a history of prior myocardial infarction. 
11.1.5 Anti-platelet therapy 
11.1.5.1 Aspirin 
Aspirin was initially recommended mainly based on a sub-group analysis of a 
Antithrombotic Trialists’ Collaboration meta-analysis which is a meta-analysis of 42 RCT’s  
published in 2002 which showed that anti-platelet therapy (primarily aspirin) reduced 
cardiovascular events by 23% in patients with symptomatic PAD including patients with IC 
(23%), those with peripheral grafts (22%) and those undergoing peripheral angioplasty 
(29%) (2002). However, this study had a lot of heterogeneity in selection criteria and 
different antiplatelet drugs used at different doses. Also the benefit of aspirin in 
asymptomatic PAD wasn’t in this meta-analysis. A more recent meta-analysis of 18 RCT’s 
including 5,269 patients with PAD, aspirin therapy alone or in combination with 
dipyridamole led to a non-significant 12% reduction in the primary end point of 
cardiovascular events(Berger et al. 2009). Two large RCT evaluated the benefit of aspirin in 
patients with asymptomatic PAD and found no benefit (Belch et al. 2008; Fowkes et al. 2010). 
However, both of these RCT’s had populations with asymptomatic PAD with very mild 
decrease in ABI and characterized as mild PAD in general. In the Prevention of Progression 
of Arterial Disease and Diabetes (POPADAD) trial enrolled patients with ABI <0.99 and the 
Aspirin for Asymptomatic Atherosclerosis trial enrolled patient with ABI 0.95 which 
calculated by using the lower pedal pressure at the ankle. In standard clinical practice and 
guidelines, ABI is calculated using the higher pedal pressure (Belch et al. 2008; Fowkes et al. 
2010). Hence, both of these studies had significant limitations in design and enrollment and 
no change in recommendation regarding anti-platelet therapy in this cohort have occurred 
(Belch et al. 2008; Fowkes et al. 2010).  
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11.1.5.2 Clopidogrel 
In a post hoc subgroup analysis of 6,452 PAD patients in The Clopidogrel versus Aspirin in 
Patients at Risk of Ischemic Events (CAPRIE) trial, the incidence of stroke, MI, or vascular 
death was reduced by 24% among those randomized to clopidogrel compared to aspirin 
monotherapy (1996).  
Dual antiplatelets therapy (DAPT) with aspirin and clopidogrel was not more effective than 
aspirin monotherapy in the Clopidogrel for High Atherothrombotic Risk and Ischemia 
Stabilization, Management and Avoidance (CHARISMA) study (Bhatt et al. 2006). However, 
post hoc analysis of the CHARISMA study revealed that DAPT was superior to aspirin 
monotherapy among patients with known symptomatic PAD at the time of enrollment 
(Bhatt et al. 2007). The combination of antiplatelet and anticoagulant therapy was evaluated 
in The Warfarin Anti-platelet Vascular Evaluation (WAVE) trial. This study found no 
incremental benefit of vitamin K antagonists when added to anti-platelet therapy for the 
prevention of cardiovascular events in patients with PAD (Anand et al. 2007). In fact, 
patients randomized to the combination of antiplatelet and anticoagulant therapy had an 
increase in life-threatening bleeding when compared with those randomized to anti-platelet 
therapy alone. 
In general, all three PAD guidelines recommend antiplatelet therapy for PAD patients. 
Selection of an antiplatelet regimen (aspirin or clopidogrel or both or other antiplatelet 
medications) for the PAD patient should be individualized on the basis of tolerance and 
other clinical characteristics (i.e., bleeding risk) along with cost and guidance from 
regulatory agencies. (Dormandy and Rutherford 2000; Hirsch et al. 2006; Network 2006; 
Rooke et al. 2011). ACC / AHA guidelines strongly recommend antiplatelet therapy to 
reduce the risk of MI, stroke, and vascular death in individuals with symptomatic 
atherosclerotic lower extremity PAD, including those with intermittent claudication or 
critical limb ischemia, prior lower extremity revascularization (endovascular or surgical), or 
prior amputation for lower extremity ischemia (class IA). They feel that antiplatelet therapy 
can be useful to reduce the risk of MI, stroke, or vascular death in asymptomatic individuals 
with an ABI less than or equal to 0.90 (Class IIa C), however do not strongly recommend it 
given lack of definite evidence of any benefit (Rooke et al. 2011).  
11.2 Medical therapy for claudication 
11.2.1 Supervised exercise program 
Many patients with PAD have severely impaired functional capacity, which leads to 
decreased quality of life (McDermott et al. 2004). A meta-analysis of 21 studies showed 
that patients with IC who underwent exercise training improved mean walking time by 
180% and maximal walking time by 120% (Gardner and Poehlman 1995). Supervised 
treadmill exercises programs are also are more effective than lower extremity resistance 
training (McDermott et al. 2009). However, due to lack of reimbursement access to this 
important therapeutic intervention has been limited. In a Cochrane review of 8 RCT’s 
evaluating supervised and unsupervised exercise among 319  participants with IC, 
statistically significant and clinically relevant improvements in maximal treadmill 
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walking distance occurred with supervised compared with non-supervised exercise 
therapy during 12 weeks to 12 months of follow up (Bendermacher et al. 2006). 
Unsupervised therapy may be less effective than supervised therapy due to lack of 
motivation, compliance with recommended exercise, lack of progression of workload in 
the absence of professional supervision and concern for personal safety to advance the 
moderate claudication discomfort severity. 
11.2.2 Pharmacological agents 
Cilastozol is an FDA-approved medication for the management of IC. It is a reversible 
phosphodiesterase inhibitor whose exact mechanism of benefit is unclear. It inhibits platelet 
aggregation, thrombin formation, and vascular smooth muscle proliferation and acts as a 
vasodilator. It also increases HDL and lowers TG levels. In an analysis of 9 RCT’s of 
cilastazol at dose of 100 mg BID, cilostazol showed a 50.7% improvement from baseline 
maximal walking distance compared to placebo (24.3%) (Pande et al. 2010). A Cochrane 
review found similar benefit (Robless et al. 2008). Given the increased incidence of sudden 
cardiac death with other phosphodiesterase inhibitors (e.g., milrinone), cilostazol is 
contraindicated in patients with heart failure and/ or ejection fraction less than 40% (Packer 
et al. 1991). The ACC/AHA guidelines have given cilostazol a grade IA recommendation for 
patients with intermittent claudication in the absence of heart failure.  
Pentoxifylline is a methylxanthine derivative that decreases blood viscosity and has 
hemorheologic (improves erythrocyte and leukocyte deformability), anti-inflammatory, and 
antiproliferative effects. Its anti-claudication effect has been inconsistent. A study 
randomizing 698 patients with IC to cilostazol, pentoxifylline or placebo did not observe any 
difference between pentoxifylline and placebo (Dawson et al. 2000). ACC/AHA guidelines 
recommend using pentoxifylline as an alternative in patients who cannot tolerate cilostazol 
or in whom cilostazol is contraindicated. 
11.2.3 Revascularization  
Revascularization is only appropriate for symptomatic patients and should not be undertaken 
as prophylactic therapy for an asymptomatic limb (Hirsch et al. 2006). Revascularization is 
indicated in patients’ with acute limb ischemia (ALI), CLI and among those with lifestyle- or 
vocation-limiting claudication who have failed a trial of medical therapy or who have highly 
favorable anatomy for endovascular therapy such as focal aorto-iliac disease (Hirsch et al. 
2006) . Data comparing medical therapy with either endovascular or surgical therapy are scant. 
The ongoing Claudication: exercise vs endoluminal revascularization (CLEVER) trial is 
comparing medical therapy alone vs. medical therapy + supervised exercise vs. medical 
therapy + endovascular therapy (Murphy et al. 2008).  
Endovascular therapy is currently the preferred mode of revascularization in cases where 
anatomy is more favorable (e.g., aorto-iliac disease). Endovascular therapy is less invasive, is 
associated with fewer complications and with shorter hospital stay as compared to bypass 
procedures. The durability of endovascular or surgical procedures depends on a number of 
factors including anatomic location (aorto-iliac revascularization whether open surgical or 
endovascular has superior long term outcomes compared with infra-inguinal 
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revascularization), lesion characteristics, technical features (e.g., angioplasty alone vs. 
angioplasty + stent, type of surgical conduit used for surgical bypass). Hybrid procedures 
are performed for multi-level in an effort to minimize the overall operative risk of the 
revascularization (e.g., iliac artery stenting followed by femoral-popliteal bypass). Open 
surgical revascularization (e.g., bypass or endarterectomy) is typically reserved for 
endovascular failures or anatomy not likely to respond to an endovascular attempt.  
12. Summary of the guideline recommendations for PAD 
In table 4 we outline the grade A level of recommendation for PAD by TASC II guidelines. 
In table 5 we outline the class I recommendations by American College of Cardiology and 
American Heart association for PAD. Finally in table 6 we outline the differences in 
recommendations between the TASC II and American College of Cardiology /American 
Heart association guidelines for management of PAD.  
 
Table 4. This table outlines TASC II grade A level of recommendation for peripheral arterial 
disease 
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Table 5. This table outlines Class I recommendations for the Identification and Management 
of Peripheral artery Disease (PAD) by American Heart Association and American College of 
Cardiology with level of evidence (LOE) 
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Table 6. This table outlines the main differences between the ACC/AHA PAD guidelines 
and TASC II guidelines are summarized in this table 
13. Conclusions  
PAD is a common disease, present in more than 8 million Americans and is associated with 
a relatively high risk of cardiovascular events. Nevertheless, it remains under-recognized by 
healthcare providers and patients alike. Increased awareness, earlier identification of the 
disease and aggressive medical therapy and vascular risk factor modification would reduce 
the likelihood of fatal and non-fatal cardiovascular events and improve overall functional 
status and quality of life.  
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rupture/disruption, this book continues with molecular, biochemical, inflammatory, cellular aspects and finally
analyzes several aspects of clinical pharmacology.
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